BELLUS Health, the drug development company focused on rare diseases, in its Q2 release importantly further delineated the timeframe for the conclusion of the Phase III Confirmatory Study for KIACTATM in AA amyloidosis, the company’s lead candidate. With circa 85% of the required events to completion having occurred the study is now expected to complete before the end of Q1 2016. Previous guidance had pointed to 2016 but with no further specificity. Top-line efficacy and safety data is
19 Aug 2015
KIACTATM data expected by mid-2016
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
KIACTATM data expected by mid-2016
Blue Star Capital Plc (BLU:LON) | 0.0 0 0.0% | Mkt Cap: 1.66m
- Published:
19 Aug 2015 -
Author:
Derren Nathan -
Pages:
7
BELLUS Health, the drug development company focused on rare diseases, in its Q2 release importantly further delineated the timeframe for the conclusion of the Phase III Confirmatory Study for KIACTATM in AA amyloidosis, the company’s lead candidate. With circa 85% of the required events to completion having occurred the study is now expected to complete before the end of Q1 2016. Previous guidance had pointed to 2016 but with no further specificity. Top-line efficacy and safety data is